title: Brain inflammation in epilepsy: experimental and clinical evidence.
abstract: Inflammatory reactions occur in the brain in various CNS diseases, including autoimmune, neurodegenerative, and epileptic disorders. Proinflammatory and antiinflammatory cytokines and related molecules have been described in CNS and plasma, in experimental models of seizures and in clinical cases of epilepsy. Inflammation involves both the innate and the adaptive immune systems and shares molecules and pathways also activated by systemic infection. Experimental studies in rodents show that inflammatory reactions in the brain can enhance neuronal excitability, impair cell survival, and increase the permeability of the blood-brain barrier to blood-borne molecules and cells. Moreover, some antiinflammatory treatments reduce seizures in experimental models and, in some instances, in clinical cases of epilepsy. However, inflammatory reactions in brain also can be beneficial, depending on the tissue microenvironment, the inflammatory mediators produced in injured tissue, the functional status of the target cells, and the length of time the tissue is exposed to inflammation. We provide an overview of the current knowledge in this field and attempt to bridge experimental and clinical evidence to discuss critically the possibility that inflammation may be a common factor contributing, or predisposing, to the occurrence of seizures and cell death, in various forms of epilepsy of different etiologies. The elucidation of this aspect may open new perspectives for the pharmacologic treatment of seizures.
authors.affiliation: Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. Vezzani@marionegri.it
authors.forename: Annamaria
authors.initials: A
authors.lastname: Vezzani
authors.forename: Tiziana
authors.initials: T
authors.lastname: Granata
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use; D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D020274:Autoimmune Diseases of the Nervous System / Q000276:immunology / Q000503:physiopathology; D001812:Blood-Brain Barrier / Q000276:immunology / Q000503:physiopathology; D002199:Capillary Permeability / Q000276:immunology; D016923:Cell Death / Q000276:immunology; D002470:Cell Survival / Q000276:immunology / Q000502:physiology; D004195:Disease Models, Animal; D004660:Encephalitis / Q000276:immunology* / Q000503:physiopathology*; D042783:Endothelial Cells / Q000276:immunology / Q000502:physiology; D004827:Epilepsy / Q000276:immunology* / Q000503:physiopathology*; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology / Q000502:physiology; D009410:Nerve Degeneration / Q000276:immunology / Q000503:physiopathology; D012640:Seizures / Q000276:immunology / Q000503:physiopathology
chemical_list: D000893:Anti-Inflammatory Agents; D000927:Anticonvulsants; D018836:Inflammation Mediators